| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 13, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/15/2024 | $4.00 | Buy | Maxim Group |
| 3/1/2023 | $3.50 | Neutral → Buy | Chardan Capital Markets |
| 8/23/2022 | $5.00 | Buy | Mizuho |
| 6/15/2022 | $8.00 | Buy | ROTH Capital |
| 6/2/2022 | $4.50 | Overweight | Cantor Fitzgerald |
| 2/28/2022 | $10.00 → $8.00 | Buy | HC Wainwright & Co. |
| 7/26/2021 | Outperform | Noble Capital Markets |
8-K - Ocugen, Inc. (0001372299) (Filer)
SCHEDULE 13G - Ocugen, Inc. (0001372299) (Subject)
8-K - Ocugen, Inc. (0001372299) (Filer)
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this
MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for net proceeds of $20.85 million, after deducting commissions and other estimated offering expenses payable by Ocugen. The financing was led by RTW Investments, with additional participation from new and existing investors. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for gross proceeds of $22.5 million, before deducting commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about January 22, 2026, subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by Ocugen. The financing is being led by RTW Investments, with additional par
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
Maxim Group initiated coverage of Ocugen with a rating of Buy and set a new price target of $4.00
Chardan Capital Markets upgraded Ocugen from Neutral to Buy and set a new price target of $3.50
Mizuho initiated coverage of Ocugen with a rating of Buy and set a new price target of $5.00
4 - Ocugen, Inc. (0001372299) (Issuer)
4 - Ocugen, Inc. (0001372299) (Issuer)
3/A - Ocugen, Inc. (0001372299) (Issuer)
MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this
MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks." This two-day event will take place from September 9-11, 2024 in New Delhi, India. "It is an honor to join the impressive group of thought leaders in this groundbreaking forum," said Dr. Musunuri. "There are endless opportunities to leverage the bes
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G/A - Ocugen, Inc. (0001372299) (Subject)
SC 13G - Ocugen, Inc. (0001372299) (Subject)
MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School
MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, November 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events section of
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial and on track for 2026 BLA filingOrthoCellix reverse merger intended to unlock the value of NeoCart/regenerative cell therapies and enable the Company to focus capital on modifier gene therapy platformSigned binding term sheet for exclusive Korean rights to OCU400 with upfront fees and near-term development milestone payments totaling up to $11 million MALVERN, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene